Trial Profile
A Phase 1, Open-Label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 Monotherapy and SNDX-6352 in Combination With Durvalumab in Patients With Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs Axatilimab (Primary) ; Durvalumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Syndax Pharmaceuticals
- 04 May 2021 Planned End Date changed from 1 Feb 2021 to 1 Aug 2021.
- 09 Sep 2020 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 09 Sep 2020 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2021.